Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose PROCRIT (Epoetin Alfa) for Anemia in Cancer Patients
NCT00337948Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Feb 2003
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 2, open-label, single-arm trial of epoetin alfa in anemia, sponsored by Johnson & Johnson. Primary endpoint: Proportion of patients achieving >= 2 g/dL Hb increase from baseline or Hb >= 12 g/dL in the Initiation Phase up to 12 weeks. Started Feb 2003; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00337948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00337948.